Self-directed and driven biotechnology entrepreneur with comprehensive accomplishments leading life sciences research, drug discovery and development, strategic alliances, grant preparation and administration, intellectual property strategy, and cross-functional teams to achieve business goals. An innovative thinker with strong directed evolution, synthetic biology, bioinformatics, and immunology acumen. Demonstrated success in pioneering scientific innovations for fast-paced, dynamic startups. Recognized for driving discovery research and early pre-clinical development programs and projects, ensuring compliance with budget, staffing, and timeline requirements. Expertise includes managing biotechnology companies, partnerships, platform technologies, and sitting on both boards of directors and scientific advisory boards. Accomplishments:• Co-founder and CSO of DiCE Molecules; industrialized Harbury DNA-encoded library platform and used it to discover potent inhibitors of multiple challenging protein-protein interface targets; advanced oral small molecule inhibitors of IL17A into pre-clinical studies.• Supported the discovery and development of ZEMDRI, an aminoglycoside antibacterial injectable.• Led team that discovered ACHN-975, the first LpxC inhibitor for the treatment of multidrug-resistant gram-negative bacterial infections advanced into clinical testing,• Led team that discovered evolved interferon-alpha (IFN-α) and advanced into Phase 1 safety studies in tandem with Roche, a global leader in pharmaceuticals and diagnostics.• Co-inventor on commercially launched glyphosate resistance trait.• Secured and administered $64M+ in grants for Achaogen and Maxygen.• Built teams of 60+ high-performing scientists.• Pioneered a fully automated, seamless-cloning capable, synthetic biology platform.• Published numerous articles and awarded 90+ U.S. patents.Expertise:Start-ups, Strategic Alliances, Entrepreneurship, Intellectual Property, Angel Investing, Venture Capital, Board of Directors, Federal Grants Management, Antibodies, Crispr, Gene Editing, Small Molecules, Agricultural Chemicals, Out-licensing, Intellectual Property Law, Patent Portfolio Management, CRO Management, Gene Synthesis, Clinical Development, Cell Biology, Assay Development, Oncology, Key Opinion Leaders, Natural Products, Clinical Trials, New Drug Application (NDA)